Histologic Evolution of Patients With Liver Transplantation

"Assessment of the Histological Evolution of Pediatric Patients With Liver Transplantation"

Certain pediatric liver transplant patients with immunosuppression levels in the therapeutic range and normal liver function tests present histological alterations (inflammation or fibrosis) in protocol biopsies.

The objective of the study was to evaluate the histological findings of protocol biopsies performed at 2, 5, 10 and 15 years after liver transplantation in pediatric patients. A follow-up biopsy is also performed 1 and 3 years after liver rejection.

To do that, a cohort study will be carried out by collecting clinical, analytical and histological data of patients undergoing post-liver transplant follow-up in pediatric hepatology and liver transplant outpatient clinics. According to the follow-up protocol for these patients, a liver biopsy is performed at 2, 5, 10 and 15 years after the transplant. In addition, ultrasound, elastography and general analysis with autoimmunity and HLA studies are carried out.

The evaluation of the histological evolution of the liver graft and its relationship with clinical and analytical changes will favor the management of immunosuppressive treatment in pediatric patients with liver transplants.

Study Overview

• Status: Recruiting
• Conditions: Children, Only; Liver Transplant Failure and Rejection
• Intervention / Treatment: Other: No interventions done (obervational)

Detailed Description

Given the increase in survival of both the graft and the transplanted patient, new questions arise regarding long-term follow-up. In general, transplant patients undergo follow-up visits that include blood tests and abdominal ultrasounds. Immunosuppression levels, graft function and possible complications (infectious, tumorous, acute or chronic rejection, renal) are monitored.

The use of immunosuppressants is mainly associated with renal, infectious complications and de novo cancer. However, insufficient levels of immunosuppression can lead to graft rejection. On the one hand, various authors have attempted to completely withdraw immunosuppressive treatment in selected patients. On the other hand, histological alterations have been evidenced in patients with normal liver function tests and who maintained serum levels of immunosuppression in the therapeutic range. The balance between these two situations in not always easy.

Hypothesis:

Certain pediatric liver transplant patients with immunosuppression levels in the therapeutic range and normal liver function tests present histological alterations (inflammation or fibrosis) in protocol biopsies.

Main objetive:

To evaluate the histological findings of protocol biopsies performed at 2, 5, 10 and 15 years after liver transplantation in pediatric patients.

STUDY PROTOCOL:

Retrospective data collection through review of medical records of pediatric liver transplant patients who meet the inclusion criteria. For the protection of personal data, the data collection form will under no circumstances contain the name or NHC, only the date of birth, weight and gender of the patient will be referenced. Each patient will be uniquely identified by an identification number (ID) that will be automatically administered by the same computer program. The correlation between the coding and the patients' personal information will be kept in written format and under lock and key in the Vall d'Hebron Hospital facilities. The demographic, clinical, analytical, ultrasound, elastographic and biopsy data of the patients will be collected. With the data collected, a database will be created that allows its analysis. The platform used to collect said data will be Certain-Li, complying with the coding requirements for patient anonymity. This is a platform developed within the framework of the international working group Graft Injury Group observing long term outcomes.

LT Follow-Up All patients received immunosuppressant treatment according to our standard protocol in accordance with current European guidelines. To monitor graft function, liver function tests were measured every 2-3 months and Doppler Ultrasound was performed annually. Liver stiffness was assessed by transient elastography (TE) using FibroScan ® (Echosens, Paris, France) with a pediatric (S) or adult (M) probe, as appropriate. TE evaluations were performed annually and whenever a follow-up biopsy was performed.

Follow-up liver biopsies Follow-up liver biopsies were obtained from patients with normal liver function tests to control histopathological changes at 2, 5, 10, and 15 years after transplantation and just before transition to adult care (aged 18 to 20 years) Diagnosis of acute liver rejection was always made by biopsy (BPAR), and rejection was graded using the Rejection Activity Index (RAI) score according to the Banff classification The fibrosis stage was assessed using the ISHAK score (0-6) in every liver biopsy

Statistical study All data collected in this registry will be provided in patient data listings. Summary tables and/or graphs will be presented for the selected parameters as appropriate to the data.

For descriptive analyses, continuous patient variables will be expressed as mean and standard deviation or median and interquartile range depending on the nature of each variable. For continuous variables, the Sudent t test for independent samples will be used, or the Mann Whitney U test when the variable does not follow a normal distribution. Fisher's exact test or the Chi-square test was used for discrete variables. The differences will be considered statistically significant with a p<0.05 (two-sided contrast). To evaluate the correlation between the follow-up time and the different variables that show liver involvement, the Pearson or Spearman coefficient will be used depending on whether or not they follow a normal distribution, respectively. The correlation coefficients will be interpreted according to the guidelines of Fleiss et al, being classified as excellent when R > 0.75, good if 0.40 ≤ R ≤ 0.75, or poor if R < 0.40. Statistical analyzes will be performed using SPSS statistical software, version 18.0 (SPSS Corporation, Chicago, IL, USA).

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Jesus Quintero, MD; Phone Number: 3140 0034 934893000; Email: jesus.quintero@vallhebron.cat
• Study Contact Backup: Name: Maria Mercadal-Hally, MD; Phone Number: 0034 675781547; Email: mariamargaret.mercadal@vallhebron.cat

Study Locations

• Spain
  • Catalunya
    • Barcelona, Catalunya, Spain, 08035
      • Recruiting
      • Hospital Universitari Vall d'Hebron
      • Contact: Paula Fernandez, MD; Phone Number: 3140 0034 93 4893000; Email: paula.fernandez@vhir.org
      • Contact: Cristina Padrós, MD; Phone Number: 3140 0034 934893000; Email: cristina.padros@vallhebron.cat

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

- Patients under 18 years of age who have received an isolated liver transplant and who are currently being monitored in the Pediatric Liver Transplant Unit of the Vall d'Hebron University Hospital

Description

Inclusion Criteria:

• Patients between 2-18 years old who have received a liver transplant at least two years ago
• Follow-up in pediatric hepatology and liver transplant outpatient clinics at the Vall d'Hebron Hospital
• Performing tests, ultrasound, elastography and biopsy during the last year as part of the follow-up protocol of our center
• Patients who have signed the informed consent for inclusion in the study and the corresponding assents.

Exclusion Criteria:

• Patients who do not meet all the inclusion criteria of the protocol.
• Patients who are transplant recipients of multiple solid organs.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Chohort of pediatric Liver transplant pacients; Patients under 18 years recipient of a Liver transplanbt followed in our Unit and under the follow-up liver biopsy protocol	Other: No interventions done (obervational); Observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sublcinical inflamation	Patients with normal liver function tests and RAI > 2 in the follow-up liver biopsy	From 15 March 2019 to 31 december 2024

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fibrosis	Any degree of fibrosis assessed using the ISHAK score observed in the follow-up liver biopsy	From 15 March 2019 to 31 december 2024
Sublcinical inflamation modification	Change in the degree of inflamation (RAI) observed between the first follow-up liver biopsy and the 1 year control (in patients with biopsy proven actute rejection)	From 15 March 2020 to 31 december 2024

Collaborators and Investigators

• Sponsor: Hospital Vall d'Hebron
• Collaborators: Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition
• Investigators: Principal Investigator: Jesus Quintero, MD, Responsible of Pediatric Hepatology and Liver Transplant Department

Publications and helpful links

General Publications

• Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM, Philogene MC, Ikle D, Poole KM, Bridges ND, Turka LA, Tchao NK. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012 Jan 18;307(3):283-93. doi: 10.1001/jama.2011.2014.
• Feng S, Demetris AJ, Spain KM, Kanaparthi S, Burrell BE, Ekong UD, Alonso EM, Rosenthal P, Turka LA, Ikle D, Tchao NK. Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. Hepatology. 2017 Feb;65(2):647-660. doi: 10.1002/hep.28681. Epub 2016 Jul 27.
• Muiesan P, Vergani D, Mieli-Vergani G. Liver transplantation in children. J Hepatol. 2007 Feb;46(2):340-8. doi: 10.1016/j.jhep.2006.11.006. Epub 2006 Dec 1.
• Feng S. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? Curr Opin Organ Transplant. 2008 Oct;13(5):506-12. doi: 10.1097/MOT.0b013e328310b0f7.

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2019
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: October 15, 2023
• First Submitted That Met QC Criteria: October 24, 2023
• First Posted (Actual): October 26, 2023

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Liver Histology; Follow-up Liver Biopsy
• Other Study ID Numbers: PR(AMI)511/2018

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IPD will be no available to other researchers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No